Shots:

• The P-III (LIBERTY-CUPID Study C) trial assessed Dupixent + SoC (H1 antihistamines) vs PBO in CSU patients (n=151, ≥6yrs.), symptomatic despite antihistamines plus treatment-naïve to omalizumab. Study A of LIBERTY-CUPID formed the basis of Japanese approval for the same
• Study reached its 1 & 2EPs at 24wks., confirming the Study A results. Data showed 8.64 vs 6.10-point reduction in itch severity & 15.86 vs 11.21-point reduction in urticaria activity, with CR in 30% vs 18%
• Safety was consistent with its known profile, with 53% TEAEs & common AEs incl. injection site reactions, accidental overdose & COVID-19 infection. Data will be submitted to the US FDA for sBLA in CSU & highlighted at upcoming conferences

Ref: Globenewswire | Image: Sanofi

Related News:- Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com